February 17, 2025 - 03:14

A harm reduction advocate has raised concerns that President Trump's tariffs on Mexico and Canada, intended to combat the flow of fentanyl into the United States, may inadvertently worsen the ongoing opioid crisis. The advocate argues that these tariffs could lead to an increase in overdose rates as the cost of necessary medical supplies and harm reduction resources rises.
By imposing tariffs, the availability of life-saving naloxone, a medication used to reverse opioid overdoses, could be jeopardized. This could create barriers for organizations working on the front lines to provide essential services to those affected by addiction.
Additionally, the advocate emphasizes that the focus should be on comprehensive strategies that address the root causes of addiction, rather than punitive measures that may hinder access to critical resources. As the nation grapples with an escalating fentanyl crisis, the implications of these tariffs warrant careful consideration to avoid further harm to vulnerable communities.
October 29, 2025 - 13:21
Evanston Community Comes Together to Support ImmigrantsEvanston business owners, nonprofit leaders, and clergy convened Tuesday morning at James Park to record a video in support of immigrants facing significant challenges. The gathering aimed to...
October 28, 2025 - 20:00
Nvidia Collaborates with Spectro Cloud to Streamline AI AdoptionNvidia has announced a strategic partnership with Spectro Cloud, a startup supported by Goldman Sachs, to address significant challenges in the adoption and management of artificial intelligence...
October 28, 2025 - 07:02
October Sees Decline in Dallas Fed Manufacturing ActivityIn October, the Dallas Federal Reserve reported a notable decline in manufacturing activity, despite a slight increase in the general business activity index. The index rose four points but still...
October 27, 2025 - 23:07
Sterling Capital to Close Underperforming Focus Equity ETFSterling Capital has announced the decision to close its Focus Equity ETF in November, citing persistent underperformance and a lack of investor demand as the primary reasons for this move. The...